RESEARCH TRIANGLE PARK, N.C.
Quintiles has received Scrip Awards’ Best Contract Research Organization honors for the second year running, and Best Technological Development in Clinical Trials for Quintiles Infosario Safety System for the first time. The Scrip Awards acknowledge excellence in the biopharmaceutical industry, based on judging by an independent panel of 15 life sciences experts. The 9th annual awards ceremony, held in London, UK, was attended by more than 400 industry leaders from around the world.
“Scrip’s Best Contract Research Organization Award is designed to acknowledge the critical role that CROs play in drug development and is always a very fiercely fought category. Quintiles impressed our judges to claim the trophy for the second year running with its commitment to innovation, particularly with Infosario Safety System. It remains the CRO to beat,” said Mike Ward, chief content officer for Datamonitor Healthcare and Scrip Intelligence, the sponsor of the Scrip Awards. “Scrip’s Best Technological Development in Clinical Trials Award recognizes the fundamental importance of using the most sophisticated platforms to leverage data captured during clinical studies. With Infosario Safety System, Quintiles was one of 13 other entries and the judges recognized the company’s cross-industry thinking in designing a product that the whole industry could use, as well as its cost savings and the step forward in patient safety that it delivers,” continued Ward.
Commenting on the Best CRO Award, Quintiles’ Paula Brown Stafford, president, Clinical Development, said: “It is an honor to be recognized once again for our sustained leadership in the sector. I’d like to dedicate this prestigious award to Quintiles’ employees worldwide – the true foundation of our business.”
The Best Technological Development in Clinical Trials Award recognized Quintiles Infosario Safety System. Richard Thomas, chief information officer, Quintiles, commented: “We’re delighted to receive this recognition for Quintiles Infosario Safety System – the result of our vision to provide a common drug safety platform for the industry. Adding best practices and Quintiles’ deep development expertise makes this platform truly transformational.”
About Quintiles
Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 28,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com.
Click here to subscribe to Mobile Alerts for Quintiles.
CONTACT
Quintiles
Charlotte Taylor, + 44 118 450 8386
Media Relations
charlotte.taylor@quintiles.com
or
Karl
Deonanan, +1-919-998-2789
Investor Relations
InvestorRelations@quintiles.com